Vironix

Using AI to Detect Heart Failure

Company Information

Website:

https://www.vironix.ai/

Sector:

Healthcare Software

Location:

Austin, TX

Every fifty-six seconds, someone dies from cardiovascular disease. Chronic-lung disease, meanwhile, is the world's third-leading cause of death.

As with many illnesses, the key to saving lives is to identify it and take action early. That’s what Vironix was designed to do.

This medical-technology company makes Artificial Intelligence-enabled therapeutic monitoring software. This helps doctors catch and intervene early on dangerous health episodes.

Vironix’s patent-pending software outperforms the current standard of care in detecting/triaging heart failure, COPD, and asthma flareups. The company completed the 2021 Mass Challenge Accelerator and has Letters of Intent that represent a $150 million annual revenue opportunity.

Team Background

Sumanth Swaminathan - Co-Founder & CEO
Sriram Ramanathan - Co-Founder & Chief Technology Officer
Christopher Landon - Co-Founder & Medical Specialist
Raising
$1.07 million
Committed
$876K (82%)
Current Valuation
$14.90 million
Min. Investment
$250
Deal Type
Title III
(For all investors)
Offering Type
Equity
Finance History
  • $126K
    2022-04-01
    Unknown
    (Priced Round)
  • $250K
    2021-03-01
    Unknown
    (Convertible Note)
Learn more on WeFunder